Best CJC-1295/Ipamorelin Providers in 2026 — Ranked & Reviewed
Two different steps of the growth-hormone release cascade are the targets here, which is why the pair is so often compounded into one stack. CJC-1295 extends the pituitary's GH pulse. Ipamorelin triggers it selectively, without raising cortisol or prolactin to any meaningful degree. Each needs a prescription and a compliant compounding pharmacy, and that second requirement is where matters currently get complicated. The status as it stands is below.
New to CJC-1295 / Ipamorelin? Read our full CJC-1295 / Ipamorelin guide — evidence, dosing, safety and side effects.
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Why nothing is ranked here yet
Nominations for CJC-1295 and for ipamorelin were both withdrawn, and neither compound appears today on Section 503A's Bulk Drug Substances List at the FDA. No 503A compounding pharmacy therefore holds a lawful basis for selling them right now, whatever an individual provider's page may claim. These two were also left out of the FDA advisory committee's positive recommendation of July 2026, which covered BPC-157, TB-500 and MOTS-c, so no approval timeline can be pointed to. A provider gets ranked here as soon as we can confirm one is legally compliant.
Listing a provider that cannot legally sell this yet would be worse than listing nobody, so nothing is shown. The FDA’s decision is being tracked, and a compliant provider will be ranked here the moment one exists.
How we rank, and what counts as “legit”
Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.
Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].
How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].
Frequently Asked Questions
Sources & methodology — as of August 2026
- 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.